Clinical relevance of KRAS and GNAS Mutationen in cell-free DNA and circulating epithelial cells regarding the development of pancreatic cancer in IPMN patients
Recruiting
- Conditions
- D13.6Pancreas
- Registration Number
- DRKS00023356
- Lead Sponsor
- niversitätsklinikum Hamburg-Eppendorf
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
IPMN diagnosis; written consent
Exclusion Criteria
no written consent
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Establishment of a liquid biopsy protocol to achieve a detailed molecular characterisation of IPMN and allow risk stratification of malignancy.
- Secondary Outcome Measures
Name Time Method We aim to analyse blood samples from 50 konservatively and 50 operatively treated IPMN patients and correlate the results of circulating epithelial cells and cell-free DNA with existing KRAS and GNAS mutations and the risk of malignancy.